This document is a publication of a patent application filed with the USPTO, specifically application US20260085318A1. It describes methods for treating cancer by employing a STAT3 double-stranded, cyclic oligonucleotide decoy in conjunction with an immune checkpoint inhibitor. The application was filed on September 20, 2023, by inventors Daniel E. Johnson and Jennifer R. Grandis.

As this is a patent application, it does not impose direct regulatory obligations or compliance deadlines on entities. However, it signifies potential future developments in cancer therapeutics and may be of interest to pharmaceutical companies, drug manufacturers, and healthcare providers involved in oncology research and treatment. The publication date is March 26, 2026.